000126600 001__ 126600
000126600 005__ 20240228140835.0
000126600 0247_ $$2doi$$a10.1038/bjc.2015.337
000126600 0247_ $$2pmid$$apmid:26461054
000126600 0247_ $$2pmc$$apmc:PMC4815783
000126600 0247_ $$2ISSN$$a0007-0920
000126600 0247_ $$2ISSN$$a1532-1827
000126600 0247_ $$2altmetric$$aaltmetric:4620010
000126600 037__ $$aDKFZ-2017-02628
000126600 041__ $$aeng
000126600 082__ $$a610
000126600 1001_ $$aGoeppert, Benjamin$$b0
000126600 245__ $$aMajor histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer.
000126600 260__ $$aEdinburgh$$bNature Publ. Group$$c2015
000126600 3367_ $$2DRIVER$$aarticle
000126600 3367_ $$2DataCite$$aOutput Types/Journal article
000126600 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521197722_1744
000126600 3367_ $$2BibTeX$$aARTICLE
000126600 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126600 3367_ $$00$$2EndNote$$aJournal Article
000126600 520__ $$aBiliary tract cancers (BTC) are rare malignant tumours with a poor prognosis. Previously, we have presented a detailed characterisation of the inflammatory infiltrate in BTC. Here, we analysed the impact of the expression of major histocompatibility complex class I (MHC I) on patient survival and the quantity, as well as the quality of tumour-infiltrating immune cell types in BTC.MHC I expression was assessed semi-quantitatively in 334 BTC, including extrahepatic (n=129) and intrahepatic cholangiocarcinomas (n=146), as well as adenocarcinomas of the gallbladder (n=59). In addition, 71 high-grade biliary intraepithelial lesions (BilIN 3) were included. Results were correlated with data on antitumour inflammation and investigated with respect to their association with clinicopathological variables and patient survival.BTC showed a wide spectrum of different MHC I expression patterns ranging from complete negativity in some tumours to strong homogenous expression in others. In BilIN 3, significantly higher MHC I expression levels were seen compared to invasive tumours (P=0.004). Patients with strong tumoural MHC I expression had a significantly higher overall survival probability (median survival benefit: 8 months; P=0.006). MHC I expression strongly correlated with the number of tumour-infiltrating T-lymphocytes (CD4(+) and CD8(+)) and macrophages.Differences of MHC I expression predict patient outcome and show correlations with specific components of the inflammatory infiltrate in BTC. These findings contribute to a better understanding of immune response and immune escape phenomena in cholangiocarcinogenesis.
000126600 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000126600 588__ $$aDataset connected to CrossRef, PubMed,
000126600 650_7 $$2NLM Chemicals$$aHistocompatibility Antigens Class I
000126600 7001_ $$aFrauenschuh, Lena$$b1
000126600 7001_ $$0P:(DE-HGF)0$$aZucknick, Manuela$$b2
000126600 7001_ $$aRoessler, Stephanie$$b3
000126600 7001_ $$aMehrabi, Arianeb$$b4
000126600 7001_ $$aHafezi, Mohammadreza$$b5
000126600 7001_ $$aStenzinger, Albrecht$$b6
000126600 7001_ $$aWarth, Arne$$b7
000126600 7001_ $$aPathil, Anita$$b8
000126600 7001_ $$aRenner, Marcus$$b9
000126600 7001_ $$aSchirmacher, Peter$$b10
000126600 7001_ $$0P:(DE-HGF)0$$aWeichert, Wilko$$b11$$eLast author
000126600 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/bjc.2015.337$$gVol. 113, no. 9, p. 1343 - 1349$$n9$$p1343 - 1349$$tBritish journal of cancer$$v113$$x1532-1827$$y2015
000126600 909CO $$ooai:inrepo02.dkfz.de:126600$$pVDB
000126600 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000126600 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000126600 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000126600 9141_ $$y2015
000126600 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2015
000126600 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126600 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126600 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126600 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000126600 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000126600 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126600 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126600 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126600 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126600 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000126600 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000126600 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000126600 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2015
000126600 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000126600 9201_ $$0I:(DE-He78)L701-20160331$$kL701$$lDKTK München$$x1
000126600 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000126600 980__ $$ajournal
000126600 980__ $$aVDB
000126600 980__ $$aI:(DE-He78)C060-20160331
000126600 980__ $$aI:(DE-He78)L701-20160331
000126600 980__ $$aI:(DE-He78)L101-20160331
000126600 980__ $$aUNRESTRICTED